Press Release: Eagle Pharmaceuticals Announces 2025 Annual Meeting Date

Dow Jones

2025/08/19

WOODCLIFF LAKE, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the "Company" or "Eagle") today announced that its 2025 Annual Meeting of Stockholders (the "2025 Annual Meeting") will be held on October 17, 2025. The specific time and place for the 2025 Annual Meeting will be specified in a notice and meeting materials to be provided to stockholders of record as of 5 p.m. Eastern Time on August 18, 2025, which is the record date for the meeting.

The Company's bylaws establish certain procedural requirements and deadlines that are applicable to annual stockholder meetings, including the 2025 Annual Meeting. A copy of the bylaws can be found at the following link: Eagle Bylaws.

About Eagle Pharmaceuticals, Inc.

Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients' lives. Eagle's commercialized products include PEMFEXY$(R)$, RYANODEX(R), BENDEKA(R), BELRAPZO(R), TREAKISYM(R) (Japan), and BYFAVO(R) and BARHEMSYS(R) through its wholly owned subsidiary Acacia Pharma Inc. Eagle's oncology and critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states, and the company is focused on developing medicines with the potential to become part of the personalized medicine paradigm in cancer care.

Investor Relations Contact

Lisa M. Wilson

T: 212-452-2793

E: lwilson@insitecony.com

(END) Dow Jones Newswires

August 18, 2025 16:58 ET (20:58 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2560359291"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2560359291\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2560359291?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-19 04:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2560359291","market":"sh","top_or_hot":-1,"title":"Press Release: Eagle Pharmaceuticals Announces 2025 Annual Meeting Date","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     WOODCLIFF LAKE, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the \"Company\" or \"Eagle\") today announced that its 2025 Annual Meeting of Stockholders (the \"2025 Annual Meeting\") will be held on October 17, 2025. The specific time and place for the 2025 Annual Meeting will be specified in a notice and meeting materials to be provided to stockholders of record as of 5 p.m. Eastern Time on August 18, 2025, which is the record date for the meeting. \n</p>\n<p>\n     The Company's bylaws establish certain procedural requirements and deadlines that are applicable to annual stockholder meetings, including the 2025 Annual Meeting. A copy of the bylaws can be found at the following link: Eagle Bylaws. \n</p>\n<p>\n     About Eagle Pharmaceuticals, Inc. \n</p>\n<p>\n     Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients' lives. Eagle's commercialized products include PEMFEXY<a href=\"https://laohu8.com/S/R\">$(R)$</a>, RYANODEX(R), BENDEKA(R), BELRAPZO(R), TREAKISYM(R) (Japan), and BYFAVO(R) and BARHEMSYS(R) through its wholly owned subsidiary Acacia Pharma Inc. Eagle's oncology and critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states, and the company is focused on developing medicines with the potential to become part of the personalized medicine paradigm in cancer care. \n</p>\n<p>\n     Investor Relations Contact \n</p>\n<p>\n     Lisa M. Wilson \n</p>\n<p>\n     T: 212-452-2793 \n</p>\n<p>\n     E: lwilson@insitecony.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 18, 2025 16:58 ET (20:58 GMT)\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Press Release: Eagle Pharmaceuticals Announces 2025 Annual Meeting Date</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPress Release: Eagle Pharmaceuticals Announces 2025 Annual Meeting Date\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-08-19 04:58</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     WOODCLIFF LAKE, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the \"Company\" or \"Eagle\") today announced that its 2025 Annual Meeting of Stockholders (the \"2025 Annual Meeting\") will be held on October 17, 2025. The specific time and place for the 2025 Annual Meeting will be specified in a notice and meeting materials to be provided to stockholders of record as of 5 p.m. Eastern Time on August 18, 2025, which is the record date for the meeting. \n</p>\n<p>\n     The Company's bylaws establish certain procedural requirements and deadlines that are applicable to annual stockholder meetings, including the 2025 Annual Meeting. A copy of the bylaws can be found at the following link: Eagle Bylaws. \n</p>\n<p>\n     About Eagle Pharmaceuticals, Inc. \n</p>\n<p>\n     Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients' lives. Eagle's commercialized products include PEMFEXY<a href=\"https://laohu8.com/S/R\">$(R)$</a>, RYANODEX(R), BENDEKA(R), BELRAPZO(R), TREAKISYM(R) (Japan), and BYFAVO(R) and BARHEMSYS(R) through its wholly owned subsidiary Acacia Pharma Inc. Eagle's oncology and critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states, and the company is focused on developing medicines with the potential to become part of the personalized medicine paradigm in cancer care. \n</p>\n<p>\n     Investor Relations Contact \n</p>\n<p>\n     Lisa M. Wilson \n</p>\n<p>\n     T: 212-452-2793 \n</p>\n<p>\n     E: lwilson@insitecony.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 18, 2025 16:58 ET (20:58 GMT)\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4232","symbol_name":"貨物陸運","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2560359291","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2560359291","pubTimestamp":1755550680,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"WOODCLIFF LAKE, N.J., Aug. 18, 2025  -- Eagle Pharmaceuticals, Inc.   today announced that its 2025 Annual Meeting of Stockholders  will be held on October 17, 2025. The specific time and place for the 2025 Annual Meeting will be specified in a notice and meeting materials to be provided to stockholders of record as of 5 p.m. Eastern Time on August 18, 2025, which is the record date for the meeting.Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients' lives. Eagle's commercialized products include PEMFEXY, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM , and BYFAVO and BARHEMSYS through its wholly owned subsidiary Acacia Pharma Inc. Eagle's oncology and critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states, and the company is ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4232":"货物陆运","BK4022":"陆运","EGRX":"Eagle制药","R":"瑞德系统","BK4139":"生物科技"},"translate_title":"新闻稿：鹰制药宣布2025年年会日期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EGRX":1,"R":1},"content_text":"WOODCLIFF LAKE, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the \"Company\" or \"Eagle\") today announced that its 2025 Annual Meeting of Stockholders (the \"2025 Annual Meeting\") will be held on October 17, 2025. The specific time and place for the 2025 Annual Meeting will be specified in a notice and meeting materials to be provided to stockholders of record as of 5 p.m. Eastern Time on August 18, 2025, which is the record date for the meeting. \n\n\n     The Company's bylaws establish certain procedural requirements and deadlines that are applicable to annual stockholder meetings, including the 2025 Annual Meeting. A copy of the bylaws can be found at the following link: Eagle Bylaws. \n\n\n     About Eagle Pharmaceuticals, Inc. \n\n\n     Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients' lives. Eagle's commercialized products include PEMFEXY$(R)$, RYANODEX(R), BENDEKA(R), BELRAPZO(R), TREAKISYM(R) (Japan), and BYFAVO(R) and BARHEMSYS(R) through its wholly owned subsidiary Acacia Pharma Inc. Eagle's oncology and critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states, and the company is focused on developing medicines with the potential to become part of the personalized medicine paradigm in cancer care. \n\n\n     Investor Relations Contact \n\n\n     Lisa M. Wilson \n\n\n     T: 212-452-2793 \n\n\n     E: lwilson@insitecony.com \n\n\n  (END) Dow Jones Newswires\n\n\n  August 18, 2025 16:58 ET (20:58 GMT)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}